IPOGrid
0001802369
IPO filing research

ADARx Pharmaceuticals, Inc.

Pharmaceutical Preparations · ADRX

ipo amended Nasdaq Global Market S-1

ADARx Pharmaceuticals, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-09-04. Current deal snapshot: exchange Nasdaq Global Market.

Filing Timeline

SEC EDGAR
S-1 filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Common · Exchange Nasdaq Global Market · Ticker ADRX · Use of proceeds To advance development of therapeutic candidates, including clinical trials, and for working capital · Underwriters J.P. Morgan Securities LLC
ADARx Pharmaceuticals, Inc. is conducting an IPO with an S-1 filing dated 2026-09-04, replacing a previous DRS/A filing. The offering includes 88,250,216 shares of common stock outstanding as of June 30, 2026, after converting convertible preferred stock into 76,920,354 shares. The filing outlines reserved shares for equity plans (2026 Plan and ESPP) and excludes unexercised options. Pro forma financials show significant net losses, with $48.4 million in six months ended June 30, 2026, and an accumulated deficit of $269.1 million as of that date.
2026-09-04 · 0001193125-26-383838
DRS/A amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
2026-07-31 · 0001193125-26-328843
DRS filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2026-06-22 · 0001193125-26-277710

Recent News

No recent news stored for this issuer.